173 related articles for article (PubMed ID: 38607409)
1. Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration.
Aljundi W; Munteanu C; Seitz B; Abdin AD
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; ():. PubMed ID: 38607409
[TBL] [Abstract][Full Text] [Related]
2. First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration.
Aljundi W; Daas L; Suffo S; Seitz B; Abdin AD
Pharmaceutics; 2024 Mar; 16(4):. PubMed ID: 38675131
[No Abstract] [Full Text] [Related]
3. First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.
Abdin AD; Aljundi W; El Jawhari K; Suffo S; Weinstein I; Seitz B
Front Pharmacol; 2022; 13():860784. PubMed ID: 35721125
[No Abstract] [Full Text] [Related]
4. Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration.
Kishi M; Miki A; Kamimura A; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M
J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568546
[TBL] [Abstract][Full Text] [Related]
5. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K; Itagaki K; Hashiya N; Wakugawa S; Tanaka K; Nakayama M; Yamamoto A; Mukai R; Honjyo J; Maruko I; Kawai M; Miyara Y; Terao N; Wakatsuki Y; Onoe H; Mori R; Koizumi H; Sekiryu T; Iida T; Okada AA;
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):43-51. PubMed ID: 37668741
[TBL] [Abstract][Full Text] [Related]
6. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy.
Szigiato A; Mohan N; Talcott KE; Mammo DA; Babiuch AS; Kaiser PK; Ehlers JP; Rachitskaya A; Yuan A; Srivastava SK; Sharma S
Ophthalmol Retina; 2024 Jan; 8(1):10-17. PubMed ID: 37673396
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration.
Pandit SA; Momenaei B; Wakabayashi T; Mansour HA; Vemula S; Durrani AF; Pashaee B; Kazan AS; Ho AC; Klufas M; Regillo C; Yonekawa Y; Hsu J; Kuriyan A; Chiang A
Ophthalmol Retina; 2024 Apr; 8(4):360-366. PubMed ID: 37913992
[TBL] [Abstract][Full Text] [Related]
8. Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration.
Cheng AM; Joshi S; Banoub RG; Saddemi J; Chalam KV
Cureus; 2023 Jun; 15(6):e40100. PubMed ID: 37425528
[TBL] [Abstract][Full Text] [Related]
9. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
10. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic.
Stanga PE; Valentín-Bravo FJ; Stanga SEF; Reinstein UI; Pastor-Idoate S; Downes SM
Eye (Lond); 2023 Oct; 37(15):3282-3289. PubMed ID: 36959312
[TBL] [Abstract][Full Text] [Related]
11. Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up).
Abdin AD; Hanifa O; Aljundi W; Munteanu C; Seitz B; Suffo S
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):457-468. PubMed ID: 37864635
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration.
Ng B; Kolli H; Ajith Kumar N; Azzopardi M; Logeswaran A; Buensalido J; Mushtaq B; Chavan R; Chong YJ
Life (Basel); 2024 Jan; 14(2):. PubMed ID: 38398702
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab.
Raimondi R; Falfeli T; Bogdanova-Bennet A; Varma D; Habib M; Kotagiri A; Steel DH; Grinton M
Ophthalmol Retina; 2024 Jun; 8(6):537-544. PubMed ID: 38040055
[TBL] [Abstract][Full Text] [Related]
14. Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History.
Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Takahashi H; Takayama T; Kawashima H; Yanagi Y
Ophthalmol Ther; 2023 Oct; 12(5):2703-2712. PubMed ID: 37531030
[TBL] [Abstract][Full Text] [Related]
15. Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Quah NQX; Javed KMAA; Arbi L; Hanumunthadu D
Clin Ophthalmol; 2024; 18():1479-1490. PubMed ID: 38827773
[TBL] [Abstract][Full Text] [Related]
16. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Jpn J Ophthalmol; 2024 Mar; 68(2):83-90. PubMed ID: 38244172
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis.
Yen WT; Wu CS; Yang CH; Chen YH; Lee CH; Hsu CR
Sci Rep; 2024 Jan; 14(1):2485. PubMed ID: 38291069
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME).
Giancipoli E; Guglielmi A; Bux AV; Clima GME; Pignatelli F; Boscia F; Viggiano P; Boscia G; Fortunato F; Besozzi G; Niro A; Dore S; Iaculli C
Ophthalmol Ther; 2024 Jun; ():. PubMed ID: 38831127
[TBL] [Abstract][Full Text] [Related]
19. Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.
Kim M; Kang JE; Park YG
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929964
[No Abstract] [Full Text] [Related]
20. Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration.
Tanaka A; Hata M; Tsuchikawa M; Ueda-Arakawa NU; Tamura H; Miyata M; Takahashi A; Kido A; Muraoka Y; Miyake M; Ooto S; Tsujikawa A
Clin Ophthalmol; 2024; 18():507-516. PubMed ID: 38405104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
